Randall James Urban

US Patent:

6579893, Jun 17, 2003

Filed:

Jun 22, 1998

Appl. No.:

09/102164

Inventors:

Randall J. Urban - Friendswood TX
Allan Green - Galveston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 3144

US Classification:

514369, 514252, 514256, 514342, 514360, 514375, 514376

Abstract:

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPAR resulting in loss of cell viability.

US Patent:

20040266834, Dec 30, 2004

Filed:

Apr 23, 2004

Appl. No.:

10/831774

Inventors:

John Copland - Houston TX, US
Slavisa Gasic - Buffalo NY, US
Randall Urban - Friendswood TX, US
Melvyn Soloff - Galveston TX, US

International Classification:

A61K031/4439
A61K031/426
A61N005/00

US Classification:

514/342000, 514/369000, 600/001000

Abstract:

The present inventions relate to the use of thiazolidinedione compounds, including troglitazone, either alone or in combination with other cancer treatments, for the treatment of cancer. These combination therapies employ thiazolidinedione compounds in conjunction with anticancer treatments, such as chemotherapeutic agents.

US Patent:

20080241107, Oct 2, 2008

Filed:

Jan 24, 2005

Appl. No.:

10/586759

Inventors:

John A. Copland III - Ponte Vedrea Beach FL, US
Randall J. Urban - Friendswood TX, US
Yvonne H. Bodenburg - Dickinson TX, US

International Classification:

A61K 35/12
C12N 5/06
A61P 3/10
C12N 15/87

US Classification:

424 937, 435375, 435377, 435455, 435383, 435366

Abstract:

The present invention concerns the use of transdifferentiated cells to treat pancreatic diseases. More particularly, it provides methods for the culture and transdifferentiation of human cord blood, cells into insulin-secreting cells. It also concerns the endocrine hormones, such as insulin, produced by such cultures, and the use of the transdifferentiated cells in the treatment of diabetes.

US Patent:

62076906, Mar 27, 2001

Filed:

Sep 3, 1999

Appl. No.:

9/389828

Inventors:

Randall J. Urban - Friendswood TX
Allan Green - Cooperstown NY

Assignee:

Board of Regents, The University Texas System - Austin TX

International Classification:

A61K31/44

US Classification:

514369

Abstract:

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR. gamma. ). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further, enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPAR. gamma. , resulting in loss of cell viability.

US Patent:

58146474, Sep 29, 1998

Filed:

Mar 4, 1997

Appl. No.:

8/811419

Inventors:

Randall J. Urban - Friendswood TX
Allan Green - Galveston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 3144
A61K 31425
A61K 3141

US Classification:

514369

Abstract:

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR. gamma. ). Troglitazone and related compounds can therefore be used to prevent excessive uterine bleeding during. Further, enhanced translocation of this orphan nuclear receptor into the nucleus of cells will block transcription in rapidly proliferating cancer cells that express PPAR. gamma. , resulting in loss of cell viability.